Drug Profile
Ceftobiprole - Basilea Pharmaceutica
Alternative Names: BAL 9141-000; BAL9141; Ro-63-9141Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica; Roche
- Class Anti-infectives; Antibacterials; Cephalosporins; Skin disorder therapies; Small molecules
- Mechanism of Action Cell wall inhibitors; Peptidyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Methicillin-resistant Staphylococcus aureus infections
- Discontinued Nosocomial infections
Most Recent Events
- 11 Oct 2023 Antimicrobial data from a preclinical trial in Enterococcal infections presented at the IDWeek 2023 (IDW-2023)
- 24 Oct 2022 Basilea Pharmaceutica announces intention to submit NDA to the US FDA for Methicillin-resistant Staphylococcus aureus infections in year-end 2022
- 24 Oct 2022 Basilea Pharmaceutica announces intention to submit NDA to US FDA for Methicillin-resistant Staphylococcus aureus infections